B2665 - Metabolomic effects of LDL cholesterol lowering genetic evidence on statins ezetimibe and PCSK9 inhibition - 21/12/2016
B number:
B2665
Principal applicant name:
Peter Würtz | University of Oulu (Finland)
Co-applicants:
George Davey Smith, Professor, MIka Ala-Korpela, Professor, Johannes Kettunen, Eeva Sliz
Title of project:
Metabolomic effects of LDL cholesterol lowering: genetic evidence on statins, ezetimibe and PCSK9 inhibition
Proposal summary:
LDL cholesterol is the primary drug target for lowering cardiovascular risk. Statins are first-line therapy, but also other drugs are approved for LDL cholesterol lowering, in particular ezetimibe and PCSK9 inhibitors. It is unknown if these 3 drugs have similar effects on the comprehensive metabolic profile for the same lowering of LDL cholesterol. Knowing the lipid lowering effects is crucial to judge the relative benefits of the drugs and understand potential mechanistic differences, which may relate to differences in efficacy on lowering cardiovascular events.
Date proposal received:
Wednesday, 6 April, 2016
Date proposal approved:
Tuesday, 19 April, 2016
Keywords:
Genetics, Cardiovascular disease, metabolic health, dyslipedimia, GWAS, Metabolomics, NMR, Biomarkers - e.g. cotinine, fatty acids, haemoglobin, etc., Cardiovascular, Genetics - e.g. epigenetics, mendelian randomisation, UK10K, sequencing, etc., Metabolic - metabolism